Natural History of Stroke: Cause and Development
NCT00009243
Recruiting
The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies. Patients 18 years of age or ol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Medstar Washington Hospital Center, Washington, District of Columbia +2 locations
Conditions: Brain Disease, Ischemic Attack, Transient, Cerebrovascular Accident, Cerebrovascular Disorder, Vascular Diseases
Register for Updates
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
NCT04585958
Recruiting
This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum resistant). Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of deoxyribonucleic acid (DNA) damage. Blocking this enzyme may help keep tumor cells from repa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +3 locations
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
Register for Updates
Natural History Study of Kaposi Sarcoma
NCT06375122
Recruiting
Background: Kaposi sarcoma (KS) is a type of tumor caused by the Kaposi sarcoma herpesvirus. KS usually affects the skin, but lesions can also appear in the lymph nodes, lungs and digestive tract. KS is most common in people with compromised immunity, but it also appears in otherwise healthy people. Researchers want to understand more about how KS develops, why it may recur, and how it affects the immune system and organs. Objective: To learn more about the natural history of KS. Eligibility... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Kaposi Sarcoma, HIV
Register for Updates
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
NCT00092235
Recruiting
Background: * Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival. * Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North America and about 50% of patients who are transplanted develop cGVHD. * Chronic GVHD is... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Graft vs. Host Disease
Register for Updates
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
NCT04639830
Recruiting
Background: During the first few decades of life, the brain changes dramatically in shape and function. Sleep lets researchers measure these changes. Researchers want to create a database of sleep and neurodevelopmental data in a group of infants and children to learn more. Objective: To address a knowledge and data gap in the field of sleep and neurodevelopment in infants and children. Eligibility: Children ages 6 months to 76 months who may or may not be at risk for neurodevelopmental and... Read More
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +4 locations
Conditions: Healthy Children, Children With Neurodevelopmental Disorders, Children With Neuropsychiatric Disorders, Children With Behavioral Syndromes
Register for Updates
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954
Recruiting
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Profound Research LLC, Carlsbad, California +36 locations
Conditions: Myasthenia Gravis, Myasthenia Gravis, MuSK
Register for Updates
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
NCT00789009
Recruiting
This study will investigate HIV infection and associated conditions by monitoring infected patients. The study will also serve as a means for recruiting HIV-infected individuals to NIAIDs ongoing clinical and laboratory studies and supporting the institute s infectious disease training program by providing Infectious Disease fellows with ongoing training in the management of HIV infection. People 18 years of age and older with suspected or confirmed HIV infection who live in the Washington, D.C... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: HIV
Register for Updates
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
NCT04890093
Recruiting
Background: The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma. Researchers want to learn if combining PEN-866 with other drugs can treat certain cancers in adolescents and young adults. Objective: To learn if the combination of PEN-866 with vincristine and temozolomide can be used to treat adolescents and young adults with solid tumors that have returned after or did not... Read More
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
04/12/2025
Locations: Childrens National Medical Center, Washington, District of Columbia +1 locations
Conditions: Sarcoma, Ewing, Rhabdomyosarcoma
Register for Updates
Filipino Family Health Initiative 1.0
NCT06569303
Recruiting
The goal of this clinical trial is to test the effectiveness of an online parenting program on Filipino parents living in California. The main aims are to: * Test the effectiveness of the online Incredible Years® model of parent training and its impact on primary outcomes. * Determine the impact of intervention engagement (i.e., higher attendance) on parenting practices and child behavior outcomes. * Describe Intervention delivery and its online implementation in real-world community settings.... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
04/12/2025
Locations: Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California
Conditions: Depression, Anxiety, Parenting
Register for Updates
Deep Brain Stimulation Therapy in Movement Disorders
NCT02119611
Recruiting
Background: - In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET). Objective: - To provide DBS treatment to people with some movement disorders. Eligibility: - Adults 18 years and older with PD, ET, or certain forms of dystonia. Design: * Participants will be screened with... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Parkinson's Disease
Register for Updates
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
NCT05078879
Recruiting
Background: Severe congenital neutropenia (SCN) is an immune system disease. People with SCN do not have enough of a kind of white blood cell called neutrophils. This means they get sick easily from infections. Some drugs to treat SCN have lots of side effects. Researchers want to see if a the drug empagliflozin can help increase the number of neutrophils in a person with SCN. Objective: To see if a drug called empagliflozin can help people with SCN. Eligibility: Adults aged 18 and older wi... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
Register for Updates
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444
Recruiting
This study is open to adults who are at least 18 years old and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic-associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Arizona Liver Health-Chandler-68733, Chandler, Arizona +403 locations
Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Register for Updates